A systematic review of methodology used in the development of prediction models for future asthma exacerbation.


Journal

BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545

Informations de publication

Date de publication:
05 02 2020
Historique:
received: 03 09 2019
accepted: 24 01 2020
entrez: 7 2 2020
pubmed: 7 2 2020
medline: 12 1 2021
Statut: epublish

Résumé

Clinical prediction models are widely used to guide medical advice and therapeutic interventions. Asthma is one of the most common chronic diseases globally and is characterised by acute deteriorations. These exacerbations are largely preventable, so there is interest in using clinical prediction models in this area. The objective of this review was to identify studies which have developed such models, determine whether consistent and appropriate methodology was used and whether statistically reliable prognostic models exist. We searched online databases MEDLINE (1948 onwards), CINAHL Plus (1937 onwards), The Cochrane Library, Web of Science (1898 onwards) and ClinicalTrials.gov, using index terms relating to asthma and prognosis. Data was extracted and assessment of quality was based on GRADE and an early version of PROBAST (Prediction study Risk of Bias Assessment Tool). A meta-analysis of the discrimination and calibration measures was carried out to determine overall performance across models. Ten unique prognostic models were identified. GRADE identified moderate risk of bias in two of the studies, but more detailed quality assessment via PROBAST highlighted that most models were developed using highly selected and small datasets, incompletely recorded predictors and outcomes, and incomplete methodology. None of the identified models modelled recurrent exacerbations, instead favouring either presence/absence of an event, or time to first or specified event. Preferred methodologies were logistic regression and Cox proportional hazards regression. The overall pooled c-statistic was 0.77 (95% confidence interval 0.73 to 0.80), though individually some models performed no better than chance. The meta-analysis had an I Current prognostic models for asthma exacerbations are heterogeneous in methodology, but reported c-statistics suggest a clinically useful model could be created. Studies were consistent in lacking robust validation and in not modelling serial events. Further research is required with respect to incorporating recurrent events, and to externally validate tools in large representative populations to demonstrate the generalizability of published results.

Sections du résumé

BACKGROUND
Clinical prediction models are widely used to guide medical advice and therapeutic interventions. Asthma is one of the most common chronic diseases globally and is characterised by acute deteriorations. These exacerbations are largely preventable, so there is interest in using clinical prediction models in this area. The objective of this review was to identify studies which have developed such models, determine whether consistent and appropriate methodology was used and whether statistically reliable prognostic models exist.
METHODS
We searched online databases MEDLINE (1948 onwards), CINAHL Plus (1937 onwards), The Cochrane Library, Web of Science (1898 onwards) and ClinicalTrials.gov, using index terms relating to asthma and prognosis. Data was extracted and assessment of quality was based on GRADE and an early version of PROBAST (Prediction study Risk of Bias Assessment Tool). A meta-analysis of the discrimination and calibration measures was carried out to determine overall performance across models.
RESULTS
Ten unique prognostic models were identified. GRADE identified moderate risk of bias in two of the studies, but more detailed quality assessment via PROBAST highlighted that most models were developed using highly selected and small datasets, incompletely recorded predictors and outcomes, and incomplete methodology. None of the identified models modelled recurrent exacerbations, instead favouring either presence/absence of an event, or time to first or specified event. Preferred methodologies were logistic regression and Cox proportional hazards regression. The overall pooled c-statistic was 0.77 (95% confidence interval 0.73 to 0.80), though individually some models performed no better than chance. The meta-analysis had an I
CONCLUSIONS
Current prognostic models for asthma exacerbations are heterogeneous in methodology, but reported c-statistics suggest a clinically useful model could be created. Studies were consistent in lacking robust validation and in not modelling serial events. Further research is required with respect to incorporating recurrent events, and to externally validate tools in large representative populations to demonstrate the generalizability of published results.

Identifiants

pubmed: 32024484
doi: 10.1186/s12874-020-0913-7
pii: 10.1186/s12874-020-0913-7
pmc: PMC7003428
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

22

Subventions

Organisme : Department of Health
ID : PDF-2015-08-044
Pays : United Kingdom

Références

Prim Care Respir J. 2013 Sep;22(3):344-52
pubmed: 23817678
BMC Pulm Med. 2009 May 19;9:24
pubmed: 19454036
PLoS Med. 2012;9(5):1-12
pubmed: 22629234
J Clin Epidemiol. 2016 Jun;74:167-76
pubmed: 26772608
NPJ Prim Care Respir Med. 2015 Mar 05;25:15004
pubmed: 25741858
BMC Med Res Methodol. 2014 Mar 19;14:40
pubmed: 24645774
Prim Care Respir J. 2011 Sep;20(3):250-6
pubmed: 21674122
Thorax. 2016 Sep;71(9):838-46
pubmed: 27044486
J Asthma. 2009 Sep;46(7):677-82
pubmed: 19728204
Eur Respir J. 2007 Sep;30(3):452-6
pubmed: 17537763
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Curr Opin Allergy Clin Immunol. 2007 Jun;7(3):223-30
pubmed: 17489039
Thorax. 2002 Mar;57(3):217-21
pubmed: 11867824
Eur Respir J. 2013 Jan;41(1):53-9
pubmed: 22653768
Stud Health Technol Inform. 2013;190:56-8
pubmed: 23823374
J Clin Epidemiol. 1998 Feb;51(2):107-18
pubmed: 9474071
J Allergy Clin Immunol. 2015 Jun;135(6):1457-64.e4
pubmed: 25258144
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1015-1024.e8
pubmed: 28017629
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Am J Respir Crit Care Med. 2009 Jan 1;179(1):19-24
pubmed: 18990678
BMJ. 2009 Mar 31;338:b604
pubmed: 19336487
Am J Respir Crit Care Med. 2005 Jan 15;171(2):109-14
pubmed: 15486340
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
BMJ Open. 2016 May 06;6(5):e011190
pubmed: 27154483
BMJ. 2013 Feb 05;346:e5595
pubmed: 23386360
Cochrane Database Syst Rev. 2016 Aug 03;(8):CD011714
pubmed: 27486836
CMAJ. 2009 Oct 27;181(9):E181-90
pubmed: 19752106
BMJ. 2015 Sep 08;351:h4438
pubmed: 26349907
Stat Med. 2016 Jan 30;35(2):214-26
pubmed: 26553135
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Allergy. 2017 Sep;72(9):1398-1405
pubmed: 28295424
Ann N Y Acad Sci. 2017 Jan;1387(1):153-165
pubmed: 27627195
CADTH Technol Overv. 2010;1(3):e0120
pubmed: 22977410
Allergy. 2009 Jan;64(1):5-17
pubmed: 19076533
Eur Respir J. 2019 Nov 14;54(5):null
pubmed: 31515399
Radiographics. 2010 Jan;30(1):13-22
pubmed: 19901087

Auteurs

Joshua Bridge (J)

Department of Eye and Vision, University of Liverpool, Liverpool, UK.

John D Blakey (JD)

Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
Medical School, Curtin University, Perth, Australia.

Laura J Bonnett (LJ)

Department of Biostatistics, University of Liverpool, Liverpool, UK. L.J.Bonnett@liverpool.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH